Stem Cell Innovations Seeks European Union Registration for Its in vitro Toxicology Suite.

Validation of ACTIVTox([R]) Would Require Product to Be Used as a Cost-Effective Alternative in European Union 

LEIDEN, The Netherlands -- Stem Cell Innovations (SCI), Inc. (OTCBB: SCLL) announced today that the Company has submitted its ACTIVTox([R]) in vitro toxicology suite to ECVAM to seek validation as an alternative to animal testing in the European Union. Toxicity testing in the pharmaceutical and chemical industries is often performed in rodents. The use of ACTIVTox would reduce the need for animals in clinical testing, saving pharmaceutical companies time and money.

ACTIVTox, SCI's proprietary highly characterized human liver cell system, is currently being used to accurately predict the response of the liver to a new drug compound. Chemists can then eliminate potential toxicity before entering clinical trials. ACTIVTox is reproducible, relevant to the human and compatible with modern high throughput drug discovery. In addition, ACTIVTox has broad application and can be used to examine toxicity in chemicals, nutraceuticals and cosmetics.

ECVAM was created by a Communication from the European Commission to the Council and the Parliament in October 1991, pointing to a requirement in Directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes, which requires that the Commission and the Member States should actively support the development, validation and acceptance of methods which could reduce, refine or replace the use of laboratory animals.

"Obtaining ECVAM approval for ACTIVTox in Europe is part of SCI's strategy to become a leading provider of alternatives for animal experiments," said CEO Dr. James Kelly. "Using our proprietary human cell models in combination with our in depth biology expertise, we will be in an excellent position to rapidly broaden our portfolio with new in vitro tests that help to reduce the number of animals used in the pharmaceutical industry."

About Stem Cell Innovations, Inc.

SCI is a cell biology company with facilities in Scotch Plains, NJ, Houston, TX and in Leiden, the Netherlands. Stem Cell Innovations proprietary, human pluripotent stem cells, known as PluriCells[TM], have the potential to aid in drug discovery, toxicology, and cell therapy.

Stem Cell Innovations is positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell[TM] technology greatly expands the Company's currently marketed C3A human liver cell-based toxicology offerings.

Additional information is available at www.stemcellinnovations.com.

Forward Looking Statement

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward looking statements. Forward-Looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because theses forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.

If any one or more or these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the difference could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.